Background and Introduction: Peripheral neuropathy is one of the most common dose-limiting side
effects of solvent-based paclitaxel. Paclitaxel poliglumex (PPX) and NK105 were developed to overcome the
paclitaxel induced peripheral neuropathy. However, the incidence of peripheral neuropathy induced by PPX
and NK105 was reported higher than solvent-based paclitaxel, but evidence remains inconsistent.
Methods: The article was reported in accordance with PRISMA Guidelines (Registration number:
CRD42021245313). We conducted a meta-analysis to compare the incidence and severity of peripheral neuropathy
between solvent-based paclitaxel, PPX and NK105 mono-chemotherapy.
Results: Results revealed that no significant difference exists between the incidence of all grade peripheral neuropathy
among the solvent-based paclitaxel, PPX and NK105 treated groups. While, the incidence of high
grade peripheral neuropathy induced by NK105 was lower than two other groups. Moreover, the overall survival
was not improved in PPX compared with other groups. However, NK105 demonstrated significant longer
overall survival in patients with cancer.
Conclusion: Current evidence suggests more attention should be paid to the paclitaxel poliglumex re-formulation.